The aim of the present study was to analyse in invasive carcinomas of the uterine cervix, the anionic glutathione S transferase (GSTi) gene, possibly implicated in the drug resistance of human cancers. Total RNA preparations obtained from invasive cervical cancers (106 specimens), carcinomas in situ (CIS) (three specimens) and normal cervical epitheliums (24 specimens) were analysed by Northern (Pastan & Gottesman, 1987; Moscow & Cowan, 1988; Endicott & Ling, 1989; D'Arpa & Liu, 1989; Beck, 1989; Giovanella et al., 1989; Tew, 1989 (Beck, 1989; Giovanella et al., 1989) . Another mechanism of action involving glutathione S transferase was described in cancer cells resistant to drugs as different as cis-platinum, alkylating agents and anthracyclines (Tew, 1989) . The anionic isoenzyme glutathione S transferase (GSTx) which belongs to a complex group of drug-detoxifying enzymes, was present at high levels in the MCF7 breast cancer cell line resistant to Doxorubicine (DXR) together with high levels of MDRI transcripts (Batist et al., 1986; . Although the precise role of GST7 in the development of resistance is not known, its expression may be one among the numerous phenotypic and biochemical changes which accompany drug resistance in some cancers.
The development of simultaneous resistance to structurally unrelated drugs is a major obstacle to chemical treatment of numerous cancers. In vitro studies performed in tumour cell lines resistant to antitumour drugs showed that several interrelated mechanisms could be involved in the resistance process (Pastan & Gottesman, 1987; Moscow & Cowan, 1988; Endicott & Ling, 1989; D'Arpa & Liu, 1989; Beck, 1989; Giovanella et al., 1989; Tew, 1989) . For example, a P-170 kDa transmembrane glycoprotein coded by a multidrug resistance (MDRI) gene is present at high levels in cell lines that are cross-resistant to anthracyclines and Vinca alkaloids (Pastan & Gottesman, 1987; Moscow & Cowan, 1988; Endicott & Ling, 1989) . P-glycoprotein acts as a drug efflux pump regulating intracellular accumulation of these drugs. DNA topoisomerases I and II are nuclear enzymes important for solving topological problems arising during DNA replication and transcription (D'Arpa & Liu, 1989 ). These enzymes have been shown to represent important targets for a variety of anticancer drugs and to play a part in resistance process of cancer cells (Beck, 1989; Giovanella et al., 1989) . Another mechanism of action involving glutathione S transferase was described in cancer cells resistant to drugs as different as cis-platinum, alkylating agents and anthracyclines (Tew, 1989) . The anionic isoenzyme glutathione S transferase (GSTx) which belongs to a complex group of drug-detoxifying enzymes, was present at high levels in the MCF7 breast cancer cell line resistant to Doxorubicine (DXR) together with high levels of MDRI transcripts (Batist et al., 1986; . Although the precise role of GST7 in the development of resistance is not known, its expression may be one among the numerous phenotypic and biochemical changes which accompany drug resistance in some cancers.
Patients with invasive carcinoma of the uterine cervix are treated by surgery, radiation and/or chemotherapy (Friedlander et al., 1983; McGuire et al., 1989 (Maniatis et al., 1982; Sheng et al., 1990 
Results
Analysis of total RNA for GSTrc transcripts Using the GSTi probe, a 0.7 kb transcript band was observed in the 51 specimens of invasive carcinoma as well as in the 12 specimens of normal cervical epitheliums which were analysed by Northern blot hybridisation (Figure 1 ). The analysis of total RNAs from the breast cancer cell lines MCF7 sensitive (MCF7/p) and resistant to doxorubicin (MCF7/DXR) provided negative and positive controls for GSTir mRNA as previously described (Batist et al., 1986) ( Figure 1 ). The transcript levels given in arbitrary units were quantitated by slot blot hybridisation relatively to the GSTir mRNA level found in the uterine cervix carcinoma cell line, CaSki, as described in Materials and methods. A representative slot blot is shown in Figure 2 . The values of the GSTr mRNA levels found in individual cervical specimens are scored in Figure 3 . High GSTt mRNA levels were found in invasive squamous cell carcinomas (mean: 2.6 ± 1.5) while low levels were detected in normal cervical epitheliums (mean: 0.7±0.1) (Student test P<10-a). Levels were also low in anaplastic cell carcinoma and sarcoma (0.5 unit) ( Table I) . Intermediary GSTi mRNA levels were found in adenocarcinomas (1.7 ± 1.3) and carcinomas in situ (1.3 ± 0.8) (Table I ). An overexpression (level superior to 1 unit) of the GSTn gene was observed in 89/106 (84%) invasive cancers while observed only in 1/24 (4%) normal cervical epithelium (P< 10-4). As shown in Figure 3, Three pairs of specimens obtained from the same patients were shown; NC-T (0.5 and 1.2 units respectively); T-M (3.5 and 8.4 units respectively); T-LN (2.9 and 2.5 units respectively). Filter was dehybridised and rehybridised using actin probe. Exposure time to Kodak XAR5 film was two days for both signals.
IV) ( Table I ). The GSTIC mRNA levels were not found to be significantly higher in recurrent tumours and lymph node metastases than in primary tumours. However, in the case of one liver metastasis treated with VCR, the GSTi mRNA level was found higher (8.5 units) than that observed in the ed (data not shown). No evidence for amplification of the GSTc gene was found in the 49 DNA preparations analysed including those from tumours where the gene was overexpressed. untreated primary tumour (3.5 units) (Figure 2) .
A previous immunohistochemical study (Shiratori et al., 1987) had suggested that the human papillomavirus (HPV), a virus most likely involved in the carcinogenesis of cervical cancers (Zur Hausen, 1989) , could favour the production of GSTc in precancerous cervical lesions. Therefore we have analysed the GSTc mRNA level in relation to the presence of HPV DNA sequences in tumours and normal cervical epitheliums. Of the 96 invasive cervical cancers for which both HPV detection (Riou et al., 1990a) and GSTi analysis could be done, no difference in GSTi mRNA levels was found between HPV-positive (85% of tumours) and HPVnegative tumours. For epidermoid carcinomas, the mean levels of GSTi mRNA were 2.6 U for both HPV-positive and HPV-negative tumours. For adenocarcinomas these mean levels were 1.6 and 2.2 for HPV-positive and HPVnegative tumours respectively. Moreover the GSTic mRNA level was not found to be significantly higher in the four HPV-positive than in the 11 HPV-negative normal cervices. The normal cervical epithelium which displays more than 2 units (Figure 3 ) was HPV-negative.
Analysis of tumoral DNA for GSTit gene amplification Forty-nine preparations of genomic DNA from cervical cancers (40 samples) and normal cervices (nine samples) were analysed by Southern blot hybridisation using GSTic probe. As expected, two DNA bands of 6.2 and 5.0 kb were observCervical cancers are treated by surgery, radiation and cytotoxic drugs (Friedlander et al., 1983; Haie et al., 1988; McGuire et al., 1989) . Treatment depends on prognosis which is determined by clinicopathological parameters of which the most important are clinical stage at diagnosis and nodal status (Pejovic et al., 1981) . However in most cases, cervical cancers respond poorly to chemotherapy. Therefore, the present study was designed to test whether the GSTt gene, suspected of involvement in drug resistance, was overexpressed in cervical cancer cells.
Using Northern blot hybridisation techniques we detected in the cervical tissues the expected 0.7 kb GSTc transcript band (Figure 1 ). Transcripts were easily detectable in all the specimens analysed. When normalised to actin mRNA, GSTi transcript levels in squamous cell carcinomas were found to undergo variations (range 0.5 to 8 units), but no significant difference was observed between cancers of different clinical stages suggesting that GSTi is not associated with the progression of cervical cancers. In one liver metastasis the GSTic mRNA level was found to be higher than in the primary tumour. This could however be due to the presence of normal tissue in the primary tumour. A significant difference of the frequency of tumours with GSTic overexpression (P<0.01) was found between squamous cell carcinomas and cancers of other histological types (adenocarcinomas, anaplastic cell carcinoma and sarcoma).
Our data confirmed previous immunohistochemical studies (Shiratori et al., 1987) showing a GSTn expression in about 90% of invasive cervical cancers. However they differ from those of Shiratori et al. (1987) (Riou et al., 1990b) suggesting that expression of this gene may also be involved in the drug resistance phenotype of certain cervical cancers.
In conclusion, it is most likely that several mechanisms are involved in the drug resistance of invasive cervical cancers. 
